Skip to main content
Sikander Ailawadhi on Muck Rack

Sikander Ailawadhi

As seen in: Nature, Wiley, Wiley Online Library, PLOS ONE, MDPI, Taylor & Francis Online, Medscape, The Lancet, Dove Medical Press, HemOnc Today and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sikander

Contact Sikander, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

07 Harnessing Machine Learning to Measure Access to Health Care

|
By Xueying Zhao, Tim Cortese, Sikander Ailawadhi
| ONCOLOGY journal Verified
Objectives Are you aware of how your community’s health requirements are being addressed? Ensuring equitable health care accessibility endows all individuals with equal opportunities for care, regardless of their socioeconomic variances. Prior studies have shown that economically disadvantaged communities frequently experience elevated breast cancer mortality rates within the US. Materials and Methods We modeled breast cancer mortality rates using a Gaussian linear regression model.
Open in Who Shared Issue with article?

FDA Approves Gedatolisib for HR+/HER2- Metastatic Breast Cancer

|
By Alex Biese Verified, Sikander Ailawadhi, Donna Berizzi
| Oncology Nursing News Verified
The Food and Drug Administration (FDA) has approved gedatolisib (Revtorpyk) for use in combination with fulvestrant, with or without palbociclib. This approval specifically targets adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.
Open in Who Shared View Duplicates (4) Issue with article?

FDA Approves Gedatolisib for HR+, HER2– PIK3CA Wild-Type Advanced Breast Cancer

|
By Ariana Pelosci Verified, Tim Cortese, Sikander Ailawadhi
| ONCOLOGY journal Verified
The FDA has approved gedatolisib (Revtorpyk) in combination with fulvestrant with or without palbociclib (Ibrance) for patients with hormone receptor (HR)–positive, HER2-negative (HER2–), PIK3CA wild-type advanced breast cancer following disease progression on or after at least 1 line of endocrine therapy.¹ “In my opinion, I think this could be immediately practice changing.
Open in Who Shared Issue with article?
See all 74 licensed articles (122 Total)